Treatment of Relapsed/Refractory Myeloma

P-226: Safety and clinical activity of belantamab mafodotin combined with carfilzomib, lenalidomide, and dexamethasone after at least one prior line of therapy, interim results from phase 1 clinical trial.

P-227: Safety and clinical activity of ruxolitinib combined with carfilzomib and dexamethasone for patients with carfilzomib-refractory multiple myeloma:Rresults from a phase 1 clinical trial.

P-230: Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study

P-231: ABBV-383, a BCMA-CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: A Multicenter, Phase 1b Dose Optimization Study With Step-up Dosing

P-232: Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment

P-233: Physician perspectives regarding conventional marrow testing and MRD assessments to guide decision-making in myeloma

P-234: DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS – REAL WORLD EVIDENCE – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

P-238: A Real-World Observational Study of Belantamab Mafodotin (Belamaf) as a Treatment for Relapsed/Refractory Multiple Myeloma (RRMM)

P-240: Efficacy and Safety of Cilta-Cel and T-Cell Phenotype Analyses in Patients With Relapsed/Refractory Multiple Myeloma and Prior Non-Cellular Anti-BCMA Therapy: Phase 2 CARTITUDE-2 Cohort C

P-242: Real-world treatment patterns and clinical outcomes amongst patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody

P-244: Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison.

P-245: Belantamab mafodotin in patients with severely impaired renal function: a phase I, 2-part study to evaluate pharmacokinetics, safety and efficacy in patients with relapsed/refractory multiple myeloma

P-246: Real-world attrition rates after second-line therapy or later in patients from the Flatiron database with relapsed/refractory multiple myeloma refractory to lenalidomide

P-247: Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): Analysis of the LINKER-MM1 study

P-248: REAL-WORLD OUTCOMES OF TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS BY TREATMENT EXPERIENCE: THE ASSOCIATION OF PRIOR LINES AND PENTA-REFRACTORINESS WITH PROGRESSION-FREE AND OVERALL SURVIVAL

P-249: THE ASSOCIATION BETWEEN AGE, PERFORMANCE STATUS, FRAILTY AND OUTCOMES IN REAL-WORLD CLINICAL PRACTICE AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

P-250: THE RELATIONSHIP OF EXTRAMEDULLARY DISEASE AND HIGH-RISK CYTOGENETICS ON REAL-WORLD OUTCOMES AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

P-251: VARIATION IN REAL-WORLD OUTCOMES AMONG PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA ACROSS CLINICAL SUBGROUPS: A GERMAN REGISTRY ANALYSIS

P-252: Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed/refractory multiple myeloma

P-254: Cardiac and hidden toxicity of Carfilzomib in presence of Cardiometabolic Syndrome and Early-Stage Heart Failure with reduced Ejection Fraction.

P-255: Efficacy of a Second Autologous Stem Cell Transplant for Multiple Myeloma and Correlation with Response to Initial Transplant: A Single-Center Experience

P-256: Initial Report of a Single Institution Experience with Teclistamab for Relapsed or Refractory Multiple Myeloma Including Prior BCMA

P-257: Real-world treatment patterns and clinical outcomes among patients with triple-class exposed (TCE) multiple myeloma (MM)

P-259: Targeting Ubiquitin Chains With Cyclic Peptides For The Treatment Of Multiple Myeloma

P-263: Treatment patterns and clinical outcomes in multiple myeloma patients previously treated with lenalidomide and an anti-CD38 monoclonal antibody: findings from the PREAMBLE registry

P-264: A Phase 1b Study of Isatuximab and Bendamustine for Triple-Class Refractory Multiple Myeloma

P-265: Mezigdomide (MEZI) monotherapy in relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial

P-266: Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma

P-268: AN INNOVATIVE INTERACTIVE CASE-BASED ONLINE EDUCATION TOOL SIGNIFICANTLY INCREASES KNOWLEDGE AND COMPETENCE OF CLINICIANS MANAGING TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

P-269: EFFECTIVENESS OF ONLINE EDUCATION IN IMPROVING KNOWLEDGE, COMPETENCE AND CONFIDENCE OF PHYSICIANS IN THE MANAGEMENT OF MULTIPLE MYELOMA

P-270: EFFECTIVENESSS OF MICRO CME AT IMPROVING CLINICAL KNOWLEDGE AND COMPETENCE RELATED TO BCMA-TARGETED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

P-271: Online CME improves clinical decision-making in the management of patients with relapsed/refractory multiple myeloma

P-272: Belantamab Mafodotin For Relapsed/Refractory Multiple Myeloma: A Real-World Observational Study Update

P-273: Isatuximab monotherapy or combination therapy with dexamethasone in older adult patients with relapsed/refractory multiple myeloma: a single institution experience

P-274: Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): A pooled analysis from the MagnetisMM studies

P-275: CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

P-276: Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy

P-277: Venetoclax Versus Bortezomib, in Combination with Daratumumab and Dexamethasone, in Patients With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

P-278: Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States

P-282: Ranking Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma (RRMM): International Physician Panel Consensus following a Systematic Review of the Literature

P-283: Systematic literature review of prognostic factors for relapsed/refractory multiple myeloma

P-284: Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study)

P-285: Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connect® Multiple Myeloma Disease Registry

P-286: Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: Post-hoc analysis from MagnetisMM-3

P-287: Isatuximab Plus Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma in Real Life Context in France: IMAGE Subgroup Analysis Based on Subgroups of Interest

P-288: A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T treatment

P-289: The efficacy and safety of Prednisone, Cyclophosphamide, Doxorubicin and Carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy.

P-290: Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel

P-293: Real-World Treatment Patterns and Outcomes in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey

P-294: Comparative Effectiveness of Teclistamab vs Real-world Physician’s Choice of Therapy in the LocoMMotion and MoMMent Studies for Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma

P-295: Efficacy, Survival and Safety of Selinexor, Bortezomib and Dexamethasone (SVd) in Patients with Lenalidomide-Refractory Multiple Myeloma: Subgroup Data from the BOSTON Trial

P-296: LIGHTHOUSE: MELFLUFEN, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA REFRACTORY TO AN IMID AND A PROTEASOME INHIBITOR OR WITH ≥3 PRIOR LINES OF THERAPY

P-297: Selinexor, bortezomib, and dexamethasone in patients with previously treated multiple myeloma: updated results of BOSTON trial by prior therapies

P-298: Retrospective study of treatment patterns and clinical outcomes by race in patients with triple-class-exposed multiple myeloma treated in a real-world setting

P-299: Survival Outcomes in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Either IMiD- or Non-IMiD-Based Regimens After Triple-Class Exposure in the PREAMBLE Registry

P-302: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)—FINAL EFFICACY AND SAFETY RESULTS

P-305: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA (MM) WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS

P-306: Final results of a Phase 1b study of subcutaneous isatuximab administration by an on-body delivery system (OBDS) plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

P-307: Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: A post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria

P-309: ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples

P-310: Treatment Preferences Among Triple-class Exposed Patients With Relapsed/Refractory Multiple Myeloma in the United States (US), United Kingdom (UK), and Germany (DE): a Discrete Choice Experiment

P-312: Impact of the IF system using HYDRASHIFT® on response evaluation for patients under treatment with the IgG-κ monoclonal antibody, isatuximab

P-313: ALLG MM25 (VIBER-M): A Phase Ib/II study of Venetoclax, Iberdomide and Dexamethasone for patients in first or second relapse of Multiple Myeloma with t(11;14)

P-314: Bendamustine Salvage for Relapsed – Refractory Multiple Myeloma: A retrospective analysis of outcomes in heavily pretreated patients.

P-315: Elranatamab exposure-safety analysis in patients with relapsed/refractory multiple myeloma: Analysis from MagnetisMM studies

P-316: NK cell kinetics predict outcome in the multiple treated with elotuzumab, lenalidomide plus dexamethasone (ERd): a subanalysis in Japanese multicenter observation for once monthly ERd study.

P-317: How do patients and providers value innovative multiple myeloma treatments? Evidence from a discrete choice experiment

P-318: The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

P-319: Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA

P-320: Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial

P-321: Real-World Outcomes In Myeloma Patients With t(11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

P-322: Real world outcomes of belantamab mafodotin from the UK and Ireland: updated results.

P-323: A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone Versus Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

P-324: LocoMMotion: A prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up

P-325: Standard of Care (SOC) Outcomes in the Last 3 Years in Patients With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): The First Pooled Analysis of LocoMMotion and MoMMent Trials

P-326: Genome-wide CRISPR screen identifies SPOP as a modulator of IMiDs sensitivity in multiple myeloma

P-328: Talquetamab vs Real-World Physician’s Choice of Therapy (RWPC): Comparative Efficacy in Patients (pts) With Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

P-329: A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma

P-331: Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma

P-492: Pharmacodynamic Effects of Tiragolumab, as Monotherapy and In Combos with Daratumumab and Atezolizumab in Patients with R/R MM: Biomarker Results From a Phase 1a/1b Trial

P-506: Single Centre Experience with BCMA-directed Bispecific T Cell Engagers (BiTE) via the Compassionate Access Schemes in Patients with Heavily Pre-Treated Relapsed or Refractory Multiple Myeloma (RRMM)